Unicycive Therapeutics (UNCY) Accounts Payables (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Accounts Payables data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 8.87% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 8.87% YoY), and the FY2025 full-year result was $383000.0, down 63.8% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.1 million, up from $383000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $2.0 million in Q4 2023 and bottomed at $383000.0 in Q4 2025.
• The 5-year median for Accounts Payables is $800000.0 (2022), against an average of $926647.1.
• The widest annual swing landed in 2022, when Accounts Payables soared 1532.65%; it then sank 63.8% in 2025.
• A 5-year view of Accounts Payables shows it stood at $846000.0 in 2022, then surged by 136.41% to $2.0 million in 2023, then plunged by 47.1% to $1.1 million in 2024, then tumbled by 63.8% to $383000.0 in 2025, then soared by 197.65% to $1.1 million in 2026.
• The last three Accounts Payables figures came in at $1.1 million (Q1 2026), $383000.0 (Q4 2025), and $717000.0 (Q3 2025), per Business Quant data.

Peer Comparison